Affiliation
Rockingham General Hospital, Cooloongup, WA, AustraliaIssue Date
2015-06-23
Metadata
Show full item recordCitation
The place of PD-1 inhibitors in melanoma management. 2015: Lancet OncolJournal
The Lancet. OncologyDOI
10.1016/S1470-2045(15)00094-7PubMed ID
26115798Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(15)00094-7
Scopus Count
Collections
Related articles
- [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
- Authors: Fløe LE, Svane IM, Bastholt L, Schmidt H
- Issue date: 2016 Aug 15
- Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
- Authors: Lim SY, Menzies AM, Rizos H
- Issue date: 2017 Jun 1
- [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
- Authors: Yamazaki N, Maeda Y
- Issue date: 2015 Apr
- PD-1 Blockers.
- Authors: Wolchok JD
- Issue date: 2015 Aug 27
- The new paradigm of systemic therapies for metastatic melanoma.
- Authors: Volpe VO, Klufas DM, Hegde U, Grant-Kels JM
- Issue date: 2017 Aug